These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Safety analysis of dust mite allergen for diagnosis and immunotherapy of asthma and rhinitis]. Wen T; Cai Y; Chen X; Xiang L; Wang B; Zhuang Y Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1999; 17(5):274-6. PubMed ID: 12563856 [TBL] [Abstract][Full Text] [Related]
4. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072 [TBL] [Abstract][Full Text] [Related]
5. Immediate adverse reactions to immunotherapy. Can D; Demir E; Tanaç R; Gülen F; Yenigün A J Investig Allergol Clin Immunol; 2003; 13(3):177-80. PubMed ID: 14635467 [TBL] [Abstract][Full Text] [Related]
6. [Adverse reactions to immunotherapy in pediatric patients]. Avila Castañón L; Lerma-Ortiz L; Velázquez Armenta Y; del Rio Navarro BE; Sienra Monge JJ Rev Alerg Mex; 2003; 50(5):182-6. PubMed ID: 14631589 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Moreno C; Cuesta-Herranz J; Fernández-Távora L; Alvarez-Cuesta E; Clin Exp Allergy; 2004 Apr; 34(4):527-31. PubMed ID: 15080803 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy]. Ibáñez Sendín MD Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375 [TBL] [Abstract][Full Text] [Related]
10. Safety of sublingual grass pollen immunotherapy after anaphylaxis. Nichani JR; de Carpentier J J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039 [TBL] [Abstract][Full Text] [Related]
11. [Study on safty of standardized specific mite-allergen immunotherapy to children with allergic rhinitis and/or asthma]. Wu Y; Long Z; Huang Y; Huang X Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Jul; 25(14):641-4. PubMed ID: 22032122 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide. Wüthrich B; Gumowski PL; Fäh J; Hürlimann A; Deluze C; André C; Fadel R; Carat F J Investig Allergol Clin Immunol; 2001; 11(3):149-56. PubMed ID: 11831445 [TBL] [Abstract][Full Text] [Related]
13. Rhinitis and asthma co-morbidity in respiratory allergy due to house dust mite: results of an observational open controlled parallel group study in real-life setting. Marogna M; Spadolini I; Massolo A Eur Ann Allergy Clin Immunol; 2005 Apr; 37(4):135-42. PubMed ID: 15916014 [TBL] [Abstract][Full Text] [Related]
14. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Ragusa VF; Massolo A Eur Ann Allergy Clin Immunol; 2004 Feb; 36(2):52-5. PubMed ID: 15061395 [TBL] [Abstract][Full Text] [Related]